Objective: The goal of this study was to test the hypothesis that responses to the McGill Pain Questionnaire are predictive of adjunctive neuropathic pain medication use by women with lichen sclerosus (LS).
Materials and Methods: This is a retrospective chart review of 430 women with vulvar LS treated at a tertiary referral vulvar care clinic. Demographics, responses to the McGill Pain Questionnaire, and use of neuropathic pain medications were collected. Bivariate and multivariable logistic regression analyses were performed to identify factors significantly associated with use of neuropathic pain medications.
Results: Of the 430 subjects, 119 (27.7%) used neuropathic pain medications for vulvar pain. Factors significantly associated with use of these medications include lower body mass index (odds ratio [OR] = 0.96, p = .02), non-White race (OR = 2.97, p = .05), and total McGill Pain Questionnaire score (OR = 1.05, p < .001).
Conclusions: Vulvar pain is a common presenting symptom in women with LS. Responses to the McGill Pain Questionnaire may be helpful in the long-term management of women with LS as a screen to identify those patients who might benefit from adjunctive neuropathic pain medication use.
The McGill Pain Questionnaire can be used to identify patients with vulvar lichen sclerosus who would benefit from neuropathic pain medication use.
1Pelvic Floor Research Group and 2University of Michigan Center for Vulvar Diseases, Department of Obstetrics and Gynecology, University of Michigan Health System, Ann Arbor, MI
Reprint requests to: Mitchell B. Berger, MD, PhD, L4100 Women’s Hospital, 1500 E Medical Center Dr, SPC 5276, Ann Arbor, MI 48109–5276. E-mail: firstname.lastname@example.org
This research was supported by Michigan BIRCWH Career Development Program grant K12 HD001438.
The authors have declared they have no conflicts of interest.